CIK 0001395937 · Large accelerated filer
Syndax Pharmaceuticals Inc
Sign in to watch- Ticker
- SNDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 320162505
- Phone
- 781-419-1400
- Business address
- 730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations · Executive or director change
- 4 Planned sale Director sold 8,000 shares at $14.21 ($113,716)
- 144 Insider Sale of Securities
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 8-K Event Other events
- 4 Planned sale Chief Executive Officer sold 32,375 shares at $24.24 ($784,776)
- 144 Insider Sale of Securities
- 4 Planned sale Head of R&D, CMO sold 65,515 shares at an average $18.07 ($1,183,643)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 8-K Event Material agreement · New debt or obligation · Unregistered share sale
- 8-K Event Executive or director change · Shareholder vote results
- DEFA14A Proxy Proxy Materials
- 8-K Event Material agreement · New debt or obligation · Unregistered share sale · Other events
- 4 Open-market sale Chief Financial Officer sold 1,177 shares at $18.99 ($22,351)
- 4 Open-market sale Chief Executive Officer sold 6,847 shares at $18.99 ($130,025)
Page 1 of 33 · 658 filings